Remora Biotech is a biotherapy portfolio company with a track record of successfully turning science into life-changing biotherapies.
The comany focuses on high-impact therapeutic areas including oncology, immunology, and regenerative and aesthetic medicine — while advancing next-generation modalities such as cell and gene therapies.
Remora Biotech’s model combines scientific excellence with entrepreneurial execution to rapidly translate innovation into value. Designed for agility and capital efficiency, it consistently delivers a higher probability of success.
From product ideation to strategic partnerships with global leaders, we have created, developed, and financed 11 companies across Switzerland and France, including Activen, Fastox Pharma (exit), Atlab Pharma (exit), Cytune Pharma (exit), OGD2 Pharma, Cellula Therapeutics, iMoon Therapeutics, Nanomunity, Radiomune Pharma, Kalsiom, and The Miniprotein™ Lab.
By building and advancing a diversified portfolio of companies, Remora Biotech is shaping the future of biotherapy and delivering meaningful impact for patients, partners, and investors.
